Affiliations: [a] Hospital Maison Blanche, Department of Neurology, Reims University Hospital, Reims, France, INSERM EA 3797 | [b] H. Lundbeck A/S, Copenhagen, Denmark
Correspondence:
[*]
Corresponding author: Serge Bakchine, Department of Neurology, Hospital Maison Blanche, 45 rue Cognacq Jay, 51092 REIMS, France. Tel./Fax: +33 3 26 78 71 35/+33 3 26 78 43 19; E-mail: sbakchine@chu-reims.fr
Abstract: Memantine is a moderate affinity, uncompetitive NMDA receptor antagonist currently approved for the treatment of moderate to severe Alzheimer's disease (AD). A 24-week, double-blind, placebo-controlled, study (Study 99679) conducted in Europe evaluated the efficacy and tolerability of 20mg/day memantine in patients with mild to moderate AD. Patients were randomised to either memantine or placebo in a 2:1 ratio. Efficacy was primarily assessed as change from baseline in ADAS-cog and CIBIC-plus score. Of 470 patients randomised and treated (memantine, n=318; placebo, n=152), 85% and 91% completed the study. Memantine-treated patients showed statistically significant improvement relative to placebo at weeks 12 and 18, and numerical superiority at week 24 on both efficacy scales. The lack of significance at week 24 was attributed to an unexpectedly high placebo response. Memantine was well tolerated with an adverse event profile similar to placebo. The data presented support the efficacy of memantine in mild to moderate AD.
Keywords: Memantine, Alzheimer's disease, mild to moderate, NMDA receptor
